Back to top
more

ProPhase Labs (PRPH)

(Delayed Data from NSDQ)

$0.31 USD

0.31
712,862

-0.02 (-4.91%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $0.31 0.00 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zoetis (ZTS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of +8.64% and +2.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of -2.27% and 18.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inotiv (NOTV) delivered earnings and revenue surprises of 25% and 3.41%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of 100% and 14.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -200% and 93.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bioventus (BVS) delivered earnings and revenue surprises of 66.67% and 5.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 0.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now

by Zacks Equity Research

ProPhase Labs (PRPH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ProPhase Labs (PRPH) delivered earnings and revenue surprises of -12.90% and 11.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 40% and 4.71%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 23.08% and 1.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 0% and 34.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eli Lilly (LLY) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of 48.48% and 14.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 10.91% and 9.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -16.67% and 3.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?

by Zacks Equity Research

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of 36.36% and 24.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -107.06% and 13.18%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -42.86% and 6.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProPhase Labs, Inc. (PRPH) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 130% and 18.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -7.35% and 12.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Catalent (CTLT) Stock Jumps 6.8%: Will It Continue to Soar?

by Zacks Equity Research

Catalent (CTLT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.